Biological Industries (BI) develops, manufactures, packs, and supplies cell culture products for academic research, diagnostic labs, hospitals, and the biotechnology and biopharmaceutical industries. BI specialises in serum-free, xeno-free, animal component-free media, as well as contract manufacturing services that range from raw material supply, through labeling and packaging, to ready-to-market product.
Orchard Therapeutics raise US-$150m
Latest NewsLondon-headquartered gene therapy Orchard Therapeutics has closed a US-$150m series C financing round to push MAAs and BLAs of three late-stage gene therapies by 2021.
Sphere Fluidics appoints Dr Tris Vaughan
AppointmentsSphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, announced today that Tris Vaughan, PhD FRSB has joined its scientific advisory board (SAB).
Artios Pharma raise €85m in Series B round
Latest NewsLife Sciences Partners and Andera Partners together with Pfizer Ventures and Novartis Venture Fund have put €85m into the cancer drug development company Artios Pharma Ltd.
Researchers remyelinate neurons
Latest NewsGerman neurogenetics at the Max-Planck-Institute for Experimental Medicine have cured the rare incurable hereditary Charcot-Marie-Tooth disease by simply supplementing the food of mice carrying the disease-causing duplication of the PMP22 gene with lecithin. The phospholipid supplementation enabled Schwann cells deficient in lipid synthesis to restore the insulating myelin sheet around peripheral neurons which is needed to speed up neuronal transmission.
A global CMO for medical media
BackgroundBiological Industries (BI) develops, manufactures, packs, and supplies cell culture products for academic research, diagnostic labs, hospitals, and the biotechnology and biopharmaceutical industries. BI specialises in serum-free, xeno-free, animal component-free media, as well as contract manufacturing services that range from raw material supply, through labeling and packaging, to ready-to-market product.
Switch for osteoporosis and obesity
Latest NewsGerman researchers have found a molecular switch that determines whether mesenchymal fibroblasts differentiate into fat- or bone-forming cells opening the avenue to modulation of the processes.
Roche presents biomarker test to identify NSCLC responders to Tecentriq
Latest NewsResearchers at Roche’s US arms Genentech and Foundation Medicine Inc. (FMI) presented a liquid biopsy test that can be used to identify NSCLC patients who respond to Roche’s PD-L1 blocker Tecentriq earlier than to FMI’s tissue based tumour mutation burden (TMB) assay.
Boehringer Ingelheim starts gene therapy collaboration for cystic fibrosis
Latest NewsGerman pharma company and CDMO Boehringer Ingelheim (BI) steps into the lucrative field of gene therapy. Together with the UK Cystic Fibrosis Gene Therapy Consortium (GTC), BI aims at developing replacement therapies compensating for mutations that lead to cystic fibrosis.
Cellectis Appoints Stefan Scherer
AppointmentsCellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Dr. Stefan Scherer, M.D., Ph.D., to the role of Senior Vice President Clinical Development and Deputy Chief Medical Officer. Dr. Scherer joins Cellectis from Novartis Pharmaceuticals Corporation, where he was the Head of Early Development, Strategy and Innovation for U.S. Oncology.
Arix Bioscience acquires 11% stake in Phamaxis Ltd.
Latest NewsAn investor consortium led by British Arix Bioscience plc has put £13.4m into the Australian Pharmaxis Ltd, which develops fibrosis inhibitors based on its amine oxidase discovery platform.